ADAR1 Capital Management LLC Lowers Holdings in Geron Co. (NASDAQ:GERN)

ADAR1 Capital Management LLC lowered its position in shares of Geron Co. (NASDAQ:GERN - Free Report) by 39.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 337,676 shares of the biopharmaceutical company's stock after selling 219,483 shares during the period. ADAR1 Capital Management LLC owned about 0.06% of Geron worth $1,195,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Nvest Financial LLC bought a new stake in shares of Geron during the fourth quarter worth about $693,000. Charles Schwab Investment Management Inc. grew its holdings in Geron by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,523,864 shares of the biopharmaceutical company's stock worth $16,014,000 after acquiring an additional 73,482 shares during the last quarter. Barclays PLC increased its position in Geron by 114.9% in the 3rd quarter. Barclays PLC now owns 1,299,912 shares of the biopharmaceutical company's stock valued at $5,902,000 after acquiring an additional 694,931 shares during the period. World Investment Advisors LLC raised its stake in shares of Geron by 10,151.4% during the third quarter. World Investment Advisors LLC now owns 1,029,553 shares of the biopharmaceutical company's stock valued at $4,674,000 after acquiring an additional 1,019,510 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its stake in shares of Geron by 519.0% during the third quarter. BNP Paribas Financial Markets now owns 205,332 shares of the biopharmaceutical company's stock valued at $932,000 after acquiring an additional 172,160 shares during the last quarter. 73.71% of the stock is currently owned by institutional investors.

Geron Stock Performance

NASDAQ GERN traded up $0.08 during trading hours on Friday, reaching $1.38. 9,210,997 shares of the company were exchanged, compared to its average volume of 11,457,756. The stock has a market capitalization of $878.93 million, a P/E ratio of -4.31 and a beta of 0.66. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. Geron Co. has a 1 year low of $1.19 and a 1 year high of $5.34. The business's 50 day simple moving average is $1.93 and its 200-day simple moving average is $3.13.

Geron (NASDAQ:GERN - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting analysts' consensus estimates of ($0.04). The firm had revenue of $47.54 million for the quarter, compared to analysts' expectations of $45.29 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. On average, equities research analysts expect that Geron Co. will post -0.25 earnings per share for the current year.

Analyst Ratings Changes

GERN has been the subject of several recent research reports. Stifel Nicolaus decreased their price target on Geron from $8.00 to $4.00 and set a "buy" rating for the company in a research note on Thursday, February 27th. Needham & Company LLC reissued a "buy" rating and set a $5.00 target price on shares of Geron in a research report on Wednesday, March 12th. Scotiabank dropped their price target on shares of Geron from $6.00 to $4.00 and set a "sector outperform" rating on the stock in a research report on Thursday, February 27th. Barclays reiterated an "overweight" rating and set a $4.00 price objective (down from $9.00) on shares of Geron in a research report on Thursday, February 27th. Finally, HC Wainwright restated a "neutral" rating on shares of Geron in a report on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $5.75.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.